Accreditation Information

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medicine (ACCME)
CEC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Upon completion of a CE Request Form, statements of credit for physicians will be issued within 30 business days.

Objectives

At the conclusion of this activity, participants will be able to:

1. Review the current status of immunotherapy in urothelial cancer, examining current and emerging clinical data with checkpoint inhibition.
2. Explore future directions of immunotherapy in urothelial cancer, including the role of sequential therapy and combination regimens.
3. Evaluate the role of predictive and prognostic biomarkers to tailor immunotherapy strategies to individual patients.
4. Identify practical strategies to prevent, anticipate, and manage immune-related adverse events in patients with urothelial cancer receiving systemic immunotherapy.

Target Audience

This activity is designed to meet the educational needs of urologists, medical oncologists, surgical oncologists, and other healthcare professionals attending the 2018 Genitourinary Cancers Symposium.

Faculty Disclosure

Planner and Faculty Disclosures

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:
Joan B. Fowler, PharmD, BCPP - has no relevant financial relationships to disclose in relation to the content of this activity.

Authors/Presenters:
Arjun V. Balar, MD - has disclosed that he is a consultant for AstraZeneca/MedImmune, Genentech, Merck, Pfizer, and Roche. He also receives grant/research support from Genentech, Merck, and Roche.

Robert Dreicer, MD, MS, MACP, FASCO - has disclosed that he is a consultant for Astellas, AstraZeneca, Bristol-Myers Squibb, EMD Serono, Orion, and Roche. He also receives grant/research support from Bayer, Genentech, and Lilly.

Ashish M. Kamat, MD, MBBS, FACS - has disclosed that he is a consultant for Abbott, AstraZeneca, Genentech, and Merck. He also receives grant/research support from FKD Therapies, Merck, and Photocure.

Peer Reviewer:
Bishoy Morris Faltas, MD - has no relevant financial relationships to disclose in relation to the content of this activity.